Telomere biology in giant cell tumour of bone

Giant cell tumour of bone (GCTB) is a benign bone tumour known for the unpredictable clinical behaviour of recurrences and, in rare instances, distant metastases. It consists of uniformly distributed osteoclastic giant cells in a background of mononuclear rounded and spindle‐shaped cells. Cytogenetically, telomeric associations are the most common chromosomal aberrations, which, however, are normally almost exclusively found in high‐grade malignancies. GCTB has often been regarded as a polyclonal tumour, but more recently a recurrent specific aberration was reported, which suggests a possible role for disturbed telomere maintenance. Here we further investigate telomere maintenance in GCTB using 19 samples from 19 patients. A combination of immunofluorescence and FISH was performed, applying antibodies directed against promyelocytic leukaemia body‐related antigen and hTERT and using telomere peptide nucleic acid probes. The TRAP assay and telomere restriction fragment length analysis were performed for functional detection of telomerase activity and alternative telomere lengthening. Both osteoclastic giant cells and mononuclear cells showed positivity for hTERT and promyelocytic leukaemia body‐related antigen. In most mononuclear cells, co‐expression was present. The TRAP assay demonstrated heterogeneous telomerase activity, while telomere restriction fragment length analysis showed non‐heterogeneous telomere lengths, indicating the absence of alternative telomere lengthening. Confocal microscopy showed stereometric co‐localization of nucleolin with promyelocytic leukaemia body‐related antigen in association with telomeres in the spindle‐shaped cells. hTERT was more diffusely distributed throughout the nucleus. Our results show that GCTB demonstrates remarkable telomere maintenance of activated telomerase and inactivated alternative telomere lengthening in the presence of normal mean telomere restriction fragment lengths. These findings strongly suggest that these aggregates, while activating telomerase, are part of a structural telomere protective‐capping mechanism rather than of a telomere‐lengthening mechanism. Telomere maintenance could be considered an important key factor in the pathogenesis of GCTB. Copyright © 2008 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

[1]  A. Cleton-Jansen,et al.  Decreased EXT expression and intracellular accumulation of heparan sulphate proteoglycan in osteochondromas and peripheral chondrosarcomas , 2007, The Journal of pathology.

[2]  Guoqiang Chen,et al.  Immunodetection of human telomerase reverse-transcriptase (hTERT) re-appraised: nucleolin and telomerase cross paths , 2006, Journal of Cell Science.

[3]  J. Karlseder Telomeric proteins: clearing the way for the replication fork , 2006, Nature Structural &Molecular Biology.

[4]  W. Hahn,et al.  Nucleolin interacts with telomerase , 2006 .

[5]  D. Amadori,et al.  Usefulness of Immunological Detection of the Human Telomerase Reverse Transcriptase , 2005, Cellular Oncology.

[6]  J. Kaufman,et al.  Telomere length versus hormonal and bone mineral status in healthy elderly men , 2005, Mechanisms of Ageing and Development.

[7]  J. Sawyer,et al.  Evidence for telomeric fusions as a mechanism for recurring structural aberrations of chromosome 11 in giant cell tumor of bone. , 2005, Cancer genetics and cytogenetics.

[8]  S. Finkelstein,et al.  Molecular analysis of primary and recurrent giant cell tumors of bone. , 2005, Cancer genetics and cytogenetics.

[9]  Dihua Yu,et al.  A robust assay for alternative lengthening of telomeres in tumors shows the significance of alternative lengthening of telomeres in sarcomas and astrocytomas. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[10]  S. Murakami,et al.  Significance of immunological detection of human telomerase reverse transcriptase: re-evaluation of expression and localization of human telomerase reverse transcriptase. , 2003, The American journal of pathology.

[11]  P. Hogendoorn,et al.  Aberrant Chemokine Receptor Expression and Chemokine Production by Langerhans Cells Underlies the Pathogenesis of Langerhans Cell Histiocytosis , 2003, The Journal of experimental medicine.

[12]  Robert A. Weinberg,et al.  Telomerase contributes to tumorigenesis by a telomere length-independent mechanism , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[13]  J. Eskew,et al.  Clonality studies in giant cell tumor of bone , 2002, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.

[14]  F. Mertens,et al.  World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Soft Tissue and Bone , 2002 .

[15]  J. Papadimitriou,et al.  The histogenesis of giant cell tumour of bone: a model of interaction between neoplastic cells and osteoclasts. , 2001, Histology and histopathology.

[16]  F. Mitelman,et al.  Cytogenetic-Morphologic Correlations in Aneurysmal Bone Cyst, Giant Cell Tumor of Bone and Combined Lesions. A Report from the CHAMP Study Group , 2000, Modern Pathology.

[17]  E. Gilson,et al.  In vitro binding of nucleolin to double-stranded telomeric DNA. , 2000, Biochemical and biophysical research communications.

[18]  R. Reddel,et al.  Telomerase-negative immortalized human cells contain a novel type of promyelocytic leukemia (PML) body. , 1999, Cancer research.

[19]  M. Mattson,et al.  Anti-apoptotic Role of Telomerase in Pheochromocytoma Cells* , 1999, The Journal of Biological Chemistry.

[20]  Bas van Steensel,et al.  TRF2 Protects Human Telomeres from End-to-End Fusions , 1998, Cell.

[21]  J. Soria,et al.  [Telomeres, telomerase and cancer]. , 1997, Bulletin du cancer.

[22]  H. Schwartz,et al.  Lack of microsatellite instability in giant cell tumor of bone. , 1996, Cancer genetics and cytogenetics.

[23]  H. Schwartz,et al.  Telomerase activity and oncogenesis in giant cell tumor of bone , 1995, Cancer.

[24]  T. Kohwi-Shigematsu,et al.  Nucleolin is a matrix attachment region DNA-binding protein that specifically recognizes a region with high base-unpairing potential , 1995, Molecular and cellular biology.

[25]  H. Schwartz,et al.  Telomere reduction in giant cell tumor of bone and with aging. , 1993, Cancer genetics and cytogenetics.

[26]  G. Dreyfuss,et al.  Nuclear proteins that bind the pre-mRNA 3' splice site sequence r(UUAG/G) and the human telomeric DNA sequence d(TTAGGG)n , 1993, Molecular and cellular biology.

[27]  J. Neff,et al.  Giant cell tumor of bone. Chromosomal analysis of 48 specimens and review of the literature. , 1992, Cancer genetics and cytogenetics.

[28]  J. Neff,et al.  Significance of chromosomal abnormalities in a malignant giant cell tumor of bone. , 1991, Cancer genetics and cytogenetics.

[29]  D. Miller,et al.  Telomeric associations and consistent growth factor overexpression detected in giant cell tumor of bone. , 1991, Cancer genetics and cytogenetics.

[30]  W. Sanger,et al.  Cytogenetic findings and biologic behavior of giant cell tumors of bone , 1990, Cancer.

[31]  G. Zajicek,et al.  Growth rate analysis of lung metastases from histologically benign giant cell tumor of Bone , 1987, Cancer.

[32]  N. Baldini,et al.  Giant-cell tumor of bone. , 1987, The Journal of bone and joint surgery. American volume.

[33]  W. Enneking,et al.  Giant-cell tumor of bone with pulmonary metastases. , 1985, The Journal of bone and joint surgery. American volume.

[34]  N. G. Sanerkin,et al.  Malignancy, aggressiveness, and recurrence in giant cell tumor of bone , 1980, Cancer.

[35]  S. Shenoy,et al.  Giant cell tumour. , 1971, Indian journal of cancer.

[36]  C. J. Campbell,et al.  Giant-cell tumor of bone. An analysis of two hundred and eighteen cases. , 1970, The Journal of bone and joint surgery. American volume.